February 3, 2025
AstraZeneca has launched new lawsuits against four generic drug manufacturers in an ongoing patent battle over its cancer drug Lynparza (olaparib), approved to treat ovarian, pancreatic, […]
January 31, 2025
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that marketing authorizations be approved for three new cancer drugs: […]
January 31, 2025
Heavy menstrual bleeding is more than an inconvenience in adolescents: It often leads to significant medical complications, in addition to disruptions in quality of life. While […]
January 31, 2025
TOPLINE: A cross-sectional survey of patients preparing for their first radiation therapy consultation found that many patients worried about the physical effects of radiation therapy, including […]
January 30, 2025
For most patients with clinical stage I-II deficient mismatch repair (dMMR) colon cancer, a single cycle of neoadjuvant pembrolizumab may be sufficient to achieve a pathologic […]
January 30, 2025
TOPLINE: Adding cetuximab (C) to postoperative radiotherapy (RT) improves disease-free survival (DFS) but not overall survival (OS) in intermediate-risk squamous cell carcinoma of the head and […]
January 29, 2025
The results of the global phase 3 LAPIS trial suggest that the addition of pamrevlumab to standard chemotherapy fails to improve survival outcomes in patients with […]
January 29, 2025
End-of-life medical care poses many dilemmas for hematologists as they consider treatment for their dying patients. Where do the wishes of patients and their loved ones […]
January 28, 2025
In the first randomized controlled trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not improve outcomes in patients with resected gallbladder […]